DelveInsight’s, “Metastatic Castration-Resistant Prostate Cancer Pipeline Insight 2023” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Metastatic Castration-Resistant Prostate Cancer pipeline landscape. It covers the Metastatic Castration-Resistant Prostate Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Castration-Resistant Prostate Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Metastatic Castration-Resistant Prostate Cancer Pipeline Report
- DelveInsight’s Metastatic Castration-Resistant Prostate Cancer pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Metastatic Castration-Resistant Prostate Cancer treatment.
- The leading companies working in the Metastatic Castration-Resistant Prostate Cancer Market include Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc., Hinova Pharmaceuticals, Taiho Oncology Inc., Forma Therapeutics Inc., Dizal Pharmaceuticals, Amgen, and others.
- Promising Metastatic Castration-Resistant Prostate Cancer Pipeline Therapies in the various stages of development include olaparib, abiraterone acetate, enzalutamide, ZEN003694, Rucaparib, and others.
- November 2023: Janssen Research & Development LLC announced a study of Phase 1 clinical trials for JNJ-78278343 and Cetrelimab. The purpose of this study is to identify the recommended phase 2 doses (RP2Ds) of JNJ-78278343 with cetrelimab (JNJ-63723283) in Part 1 (dose escalation) and to determine safety at the RP2D(s) in Part 2 (dose expansion).
- November 2023: Amunix, a sanofi company announced a study of Phase 1 & 2 clinical trials for AMX-500 (SAR446329). The study may subsequently continue via a protocol amendment with dose escalation of AMX-500 combinations (Part 3) followed by combination therapy dose expansion (Part 4). The study will be conducted in 4 parts and will commence with dose escalation of AMX-500 as a monotherapy (Part 1), followed by monotherapy dose expansion (Part 2).
- November 2023: Aragon Pharmaceuticals announced a study of Phase 1 clinical trials for Abiraterone Acetate, Prednisone and JNJ-56021927. The purpose of this study is to investigate potential drug-drug interaction (DDI) between JNJ-56021927 and abiraterone acetate and between JNJ-56021927 and prednisone, determine safety of the combination and evaluate in a descriptive manner the efficacy in these participants. It will also, potentially provide dosing recommendations for abiraterone acetate in future studies when combined with JNJ-56021927. The study will consist of a 28-day screening phase to determine eligibility, an open-label treatment phase consisting of 28-day treatment cycles, and a 30-day follow-up phase for collection of adverse events (AE) after last dose of study drug. Participants will have blood samples collected during the study to evaluate pharmacokinetics, safety, and antitumor activity (PSA).
- November 2023: Novartis Pharmaceuticals announced a study of Phase 1 & 2 clinical trials for 225Ac-PSMA-R2. The purpose of the study is to characterize the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of 225Ac-PSMA-R2 in male adult participants with metastatic castration-resistant prostate cancer (mCRPC) previously treated with androgen receptor pathway inhibitors in post-177Lu and pre-177Lu settings. This is an open label, phase I/II, multi-center study which contains two treatment groups (Group 1 and Group 2). Each group has a dose escalation part, once the Maximum Tolerated Dose/Recommended Dose for Expansion (MTD/RDE) is determined in each of the dose escalation parts, the study will continue with an expansion part in the respective group.
- November 2023: Amgen announced a study of Phase 1 clinical trials for AMG 340. This is a phase 1, open-label study evaluating the safety, clinical pharmacology and clinical activity of AMG 340, a PSMA x CD3 T-cell engaging bispecific antibody, in subjects with metastatic castrate-resistant prostate cancer (mCRPC) who have received 2 or more prior lines of therapy. The study consists of 2 parts, a monotherapy dose escalation (Arm A) and a monotherapy dose expansion (Arm B). Once the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) is identified in Arm A, Arm B will be initiated to further characterize the safety, tolerability and pharmacokinetic (PK) profile of the MTD/RP2D dose of AMG 340 monotherapy in subjects with mCRPC.
- November 2023: POINT Biopharma announced a study of Phase 3 clinical trials for Abiraterone and Enzalutamide. The purpose of this study is to evaluate the efficacy and safety of [Lu-177]-PNT2002 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with androgen receptor axis-targeted therapy (ARAT). The primary objective of the study is to determine the efficacy of [Lu-177]-PNT2002 ([Lu-177]-PSMA-I&T) versus abiraterone or enzalutamide in delaying radiographic progression in patients with mCRPC.
Request a sample and discover the recent advances in Metastatic Castration-Resistant Prostate Cancer Treatment Drugs @ Metastatic Castration-Resistant Prostate Cancer Pipeline Report
In the Metastatic Castration-Resistant Prostate Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metastatic Castration Resistant Prostate cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Metastatic Castration-Resistant Prostate Cancer Overview
Prostate cancer (PCa) is one of the most prevalent malignancies in the world and the third most common cause of male cancer-related death in the United States of America (USA). The majority of men with newly diagnosed PCa present with localized disease and undergo radical prostatectomy and/or radiological therapy, followed by androgen deprivation therapy (ADT).
Find out more about Metastatic Castration-Resistant Prostate Cancer Therapeutics Assessment @ Metastatic Castration-Resistant Prostate Cancer Preclinical and Discovery Stage Products
Metastatic Castration-Resistant Prostate Cancer Emerging Drugs Profile
- SRF617: Surface Oncology
- Rucaparib: Clovis Oncology
- HP518: Hinova Pharmaceuticals
Metastatic Castration-Resistant Prostate Cancer Pipeline Therapeutics Assessment
There are approx. 75+ key companies which are developing the therapies Metastatic Castration Resistant Prostate cancer. The Metastatic Castration-Resistant Prostate Cancer companies which have their Metastatic Castration Resistant Prostate cancer drug candidates in the most advanced stage, i.e phase III include Clovis Oncology.
DelveInsight’s Metastatic Castration-Resistant Prostate Cancer pipeline report covers around 75+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Metastatic Castration Resistant Prostate cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
Metastatic Castration-Resistant Prostate Cancer Pipeline Products have been categorized under various Molecule types such as
- Small molecule
- Cell Therapy
- Peptides
- Polymer
- Small molecule
- Gene therapy
Learn more about the emerging Metastatic Castration-Resistant Prostate Cancer Pipeline Therapies @ Metastatic Castration-Resistant Prostate Cancer Clinical Trials Assessment
Scope of the Metastatic Castration-Resistant Prostate Cancer Pipeline Report
- Coverage- Global
- Metastatic Castration-Resistant Prostate Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Metastatic Castration-Resistant Prostate Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Metastatic Castration-Resistant Prostate Cancer Companies- Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc., Hinova Pharmaceuticals, Taiho Oncology Inc., Forma Therapeutics Inc., Dizal Pharmaceuticals, Amgen, and others.
- Metastatic Castration-Resistant Prostate Cancer Pipeline Therapies- olaparib, abiraterone acetate, enzalutamide, ZEN003694, Rucaparib, and others.
Dive deep into rich insights for new drugs for Metastatic Castration-Resistant Prostate Cancer Treatment, Visit @ Metastatic Castration-Resistant Prostate Cancer Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Metastatic Castration Resistant Prostate cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Metastatic Castration Resistant Prostate cancer– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Rucaparib: Clovis Oncology
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Surface Oncology: SRF 617
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- REGN 4336: Regeneron Pharamceuticals
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- HP 518: Hinova Pharmaceuticals
- Drug profiles in the detailed report…..
- Inactive Products
- Metastatic Castration Resistant Prostate cancer Key Companies
- Metastatic Castration Resistant Prostate cancer Key Products
- Metastatic Castration Resistant Prostate cancer- Unmet Needs
- Metastatic Castration Resistant Prostate cancer- Market Drivers and Barriers
- Metastatic Castration Resistant Prostate cancer- Future Perspectives and Conclusion
- Metastatic Castration Resistant Prostate cancer Analyst Views
- Metastatic Castration Resistant Prostate cancer Key Companies
- Appendix
For further information on the Metastatic Castration-Resistant Prostate Cancer Pipeline therapeutics, reach out to Metastatic Castration-Resistant Prostate Cancer Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/major-depressive-disorder-market